Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | NNMT | P40261 | 2/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.32 |
| ▸ | CDK2 | P24941 | 3/20 | 0.32 |
| ▸ | PLK1 | P53350 | 3/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.32 |
| ▸ | PLK3 | Q9H4B4 | 3/20 | 0.32 |
| ▸ | PLK2 | Q9NYY3 | 3/20 | 0.32 |
| ▸ | TTK | P33981 | 2/20 | 0.32 |
| ▸ | AURKA | O14965 | 1/20 | 0.32 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918526 | 0.78 | LRRK2 (0.43) | LRRK2MKNK2SYKTTKPDE4A | |
| SCHEMBL9920225 | 0.67 | JAK2 (0.53) | — | |
| SCHEMBL11635133 | 0.65 | BRD4 (0.49) | HSD17B10 | |
| SCHEMBL11633395 | 0.62 | GAA (0.48) | HSD17B10 | |
| SCHEMBL10568887 | 0.61 | LMNA (0.42) | EGFR | |
| SCHEMBL10572368 | 0.61 | MAPT (0.40) | HSD17B10 | |
| SCHEMBL4325991 | 0.58 | SLC6A3 (0.50) | HSD17B10 | |
| SCHEMBL9922004 | 0.58 | KDM4E (0.41) | — | |
| SCHEMBL7837258 | 0.58 | CA1 (0.52) | — | |
| SCHEMBL9918544 | 0.56 | SMN1; SMN2 (0.44) | LRRK2SYKCCNA2CDK2PLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | LRRK2 1567/4885MKNK2 108/4885SYK 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.